Contraception method IUD,copper IUD and mirena

INTERVENTION: copper IUD Intervention 1: copper IUD. Intervention 2: mirena IUD. mirena IUD Prevention CONDITION: Sequelae of complication of pregnancy, childbirth and the puerperium Sequelae of complication of pregnancy, childbirth and the puerperium. ; Sequelae of complication of pregnancy, childbirth and the puerperium PRIMARY OUTCOME: Dysmenorrehea. Timepoint: frist visit and 1,3,6 months after IUD insertion. Method of measurement: questionnare. Quality of life. Timepoint: first visit before IUD insertion and 6 months after iud insertion. Method of measurement: questionnare. SECONDARY OUTCOME: Ackne. Timepoint: 1,3,6 months after iud insertion. Method of measurement: questionnare. Backpain. Timepoint: 1,3,6 month after iud insertion. Method of measurement: questionnare. Breast tenderness. Timepoint: 1,3,6 months after iud insertion. Method of measurement: questionnare. Discharge. Timepoint: 1,3,6 months after iud insertion. Method of measurement: questionnare. Headache. Timepoint: 1,3,6 month after iud insertion. Method of measurement: questionnare. Menorrhagia. Timepoint: 1,3,6 month after iud insertion. Method of measurement: questionnare. Spoting. Timepoint: 1,3,6 months after iud insertion. Method of measurement: questionnare. Stisfaction. Timepoint: 6 months after iud insertion. Method of measurement: questionnare. Weight gain. Timepoint: 1,3,6 months after iud insertion. Method of measurement: questionnare. INCLUSION CRITERIA: INCLUSION CRITERIA: age20‐35; normal menstruation; multi‐parity and a negative pop smear result in the previous six months. Exclusion criteria: pregnancy; abnormal menstruation (irregularity, oligomenorrhea, hypermenorrhea and menorrhagia); malignancies of uterine; ovaries and breasts; a personal and familial history of mass in breasts; uterine anomaly or myoma; pelvic inflammatory disease; psychiatric disorders; Body mass index more than 32; multi‐partnership of the individual or her spouse; chronic systemic diseases including renal failure; hepatic cirrhosis; and cardiovascular diseases; consumption of drugs related to the cardiovascular diseases